Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
NuVista, LLC operates in the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action for the company. This 1 pending office action is handled within 1 distinct art unit, indicating that the current prosecution is concentrated in 1 technical specialty.
The busiest examiner for the portfolio is TICHY, JENNIFER M.H., who is the only distinct examiner involved. This examiner is currently managing 1 pending office action. This 1 pending office action represents the total current workload for the company's patent prosecution.
The involvement of 1 distinct examiner and 1 distinct art unit suggests a centralized prosecution strategy. For a practitioner, the success of the current filing depends on the specific interpretation of TICHY, JENNIFER M.H. within that 1 art unit. The lack of multiple pending actions indicates a very focused or early stage of patent activity.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TICHY, JENNIFER M.H. | 1 | 64.6% | +34.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18125963 | SYSTEM AND METHODS FOR SOFT-TISSUE AUGMENTATION | TICHY, JENNIFER M.H. | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18125963 | SYSTEM AND METHODS FOR SOFT-TISSUE AUGMENTATION | TICHY, JENNIFER M.H. | 1653 | §103§112DP | Final Rejection | — | Pending | Mar 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNuVista, LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jennifer M.H. Tichy has the most, with 1 of NuVista, LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
